EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanoscale Drug Delivery Systems for Ovarian Cancer: Targeting Strategies, Theranostic Platforms, and Translational Challenges

Xinyue Hu, Yu Zhang, Yueda Lu, Fangqi Zheng, Kaiyu Zhang, Mengxing Jiang, Chen Chen, Zhaolian Wei iD, Jianye Wang

Small · 2026-06 · 22 (36)

DOI: 10.1002/smll.73850 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Small, online erschienen am 26.05.2026. Verfasst von Xinyue Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Theranostic Nanomedicine, Drug Delivery Systems, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 186 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science Research Project of Anhui Health Commission, Hefei Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer remains the most lethal gynecologic malignancy, primarily due to late‐stage diagnosis, peritoneal metastasis, and chemoresistance. Conventional chemotherapy is limited by poor targeting specificity and systemic toxicity, necessitating more precise therapeutic strategies. Nanoscale drug delivery systems (DDS) offer important opportunities to improve drug accumulation, reduce off‐target effects, and integrate therapeutic and diagnostic functions. In this review, we summarize major carrier platforms together with delivery strategies and theranostic approaches, while placing particular emphasis on ovarian‐cancer‐specific challenges and the translational relevance of different DDS designs. We compare key carrier systems (including hydrogels, polymeric and inorganic nanoparticles, exosomes, and liposomes) according to their relevance to ovarian‐cancer‐specific challenges such as intraperitoneal delivery, peritoneal dissemination, and postoperative residual disease. We further examine how active targeting, tumor microenvironment‐responsive release, and theranostic platforms may address these challenges, while critically assessing their practical limitations. Importantly, we highlight the major factors that continue to impede clinical translation, including biological heterogeneity, biosafety concerns, manufacturing scalability, and the limited predictive value of current preclinical models. By linking nanodesign strategies to ovarian‐cancer‐specific barriers and translational feasibility, this review aims to provide a more clinically relevant framework for the development of next‐generation precision therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsTheranostic NanomedicineDrug Delivery SystemsNanoparticlesTranslational Research, BiomedicalFemaleHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

nanoscale drug delivery systemsovarian cancertargeting strategiestheranosticstumor microenvironment

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • The First Clinical School of Anhui Medical University, Hefei, China.
  • Engineering Research Center of Biopreservation and Artificial Organs, Ministry of Education, Hefei, China.
  • Department of Surgical Oncology, Anhui Provincial Children's Hospital, Hefei, Anhui, China.

ORCID-Profile: Zhaolian Wei

Förderung

  • National Key Research and Development Program of China
  • Science Research Project of Anhui Health Commission
  • Hefei Municipal Natural Science Foundation

Zitieren

APA

Hu, X., Zhang, Y., Lu, Y., Zheng, F., Zhang, K., Jiang, M., Chen, C., Wei, Z., & Wang, J. (2026). Nanoscale Drug Delivery Systems for Ovarian Cancer: Targeting Strategies, Theranostic Platforms, and Translational Challenges. Small, 22(36). https://doi.org/10.1002/smll.73850

Vancouver

Hu X, Zhang Y, Lu Y, Zheng F, Zhang K, Jiang M, et al. Nanoscale Drug Delivery Systems for Ovarian Cancer: Targeting Strategies, Theranostic Platforms, and Translational Challenges. Small. 2026;22(36). doi:10.1002/smll.73850

BibTeX
@article{Hu2026,
  author = {Hu, Xinyue and Zhang, Yu and Lu, Yueda and Zheng, Fangqi and Zhang, Kaiyu and Jiang, Mengxing and Chen, Chen and Wei, Zhaolian and Wang, Jianye},
  title = {Nanoscale Drug Delivery Systems for Ovarian Cancer: Targeting Strategies, Theranostic Platforms, and Translational Challenges},
  journal = {Small},
  year = {2026},
  volume = {22},
  number = {36},
  doi = {10.1002/smll.73850}
}
Kostenlos starten →